We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
- Authors
Wang, Y; Wang, X-Y; Subjeck, J R; Shrikant, P A; Kim, H L
- Abstract
Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in clinical trials for melanoma. The mTOR inhibitors are also immunosuppressants and are used clinically to prevent rejection following solid-organ transplant. Novel immunotherapies are being actively developed for immunoresponsive tumours, such as RCC and melanoma.
- Publication
British journal of cancer, 2011, Vol 104, Issue 4, p643
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2011.15